Skip to main content
. 2024 Nov 26;2024(11):CD013707. doi: 10.1002/14651858.CD013707.pub2
Study Treatment 1 Treatment 2 RR 95% CI lower limit 95% CI upper limit
Shah 2013 Levosimendan + Dobutamine Milrinone + Dobutamine 0.3333 0.0142 7.8035